dichlorphenamide (Rx)

Brand and Other Names:Keveyis
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

tablet

  • 50mg

Periodic Paralysis

Indicated for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants

50 mg PO qDay or q12hr initially; increase or decrease at weekly intervals according to individual response; not to exceed 200 mg/day

Evaluate response after 2 months of treatment to decide drug should be continued

Dosing Considerations

Obtain baseline and periodic measurements of serum potassium and sodium bicarbonate

Safety and efficacy not established

Periodic Paralysis

Indicated for primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants

50 mg PO qDay or q12hr initially; increase or decrease at weekly intervals according to individual response; not to exceed 200 mg/day

Evaluate response after 2 months of treatment to decide whether drug should be continued

Use lowest effective dose possible, owing to risk increased risk of falls

Dosing Considerations

Obtain baseline and periodic measurements of serum potassium and sodium bicarbonate

Next:

Interactions

Interaction Checker

and dichlorphenamide

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (7)

            • aminosalicylic acid

              dichlorphenamide increases levels of aminosalicylic acid by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.

            • aspirin

              dichlorphenamide increases levels of aspirin by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.

            • aspirin rectal

              dichlorphenamide increases levels of aspirin rectal by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.

            • bismuth subsalicylate

              dichlorphenamide increases levels of bismuth subsalicylate by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.

            • choline magnesium trisalicylate

              dichlorphenamide increases levels of choline magnesium trisalicylate by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.

            • magnesium salicylate

              dichlorphenamide increases levels of magnesium salicylate by unspecified interaction mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.

            • salsalate

              dichlorphenamide increases levels of salsalate by unknown mechanism. Contraindicated. Coadministration of dichlorphenamide with high-dose aspirin may increase salicylate levels. Anorexia, tachypnea, lethargy, and coma reported.

            Serious - Use Alternative (1)

            • metoclopramide intranasal

              dichlorphenamide, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.

            Monitor Closely (257)

            • abiraterone

              dichlorphenamide and abiraterone both decrease serum potassium. Use Caution/Monitor.

            • acetazolamide

              dichlorphenamide and acetazolamide both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, acetazolamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • ado-trastuzumab emtansine

              dichlorphenamide and ado-trastuzumab emtansine both decrease serum potassium. Use Caution/Monitor.

            • afatinib

              dichlorphenamide and afatinib both decrease serum potassium. Use Caution/Monitor.

            • albuterol

              dichlorphenamide and albuterol both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, albuterol. Either increases levels of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • aldesleukin

              dichlorphenamide, aldesleukin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • allopurinol

              dichlorphenamide and allopurinol both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, allopurinol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • alvimopan

              dichlorphenamide and alvimopan both decrease serum potassium. Use Caution/Monitor.

            • amiloride

              dichlorphenamide, amiloride. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • amlodipine

              dichlorphenamide and amlodipine both decrease serum potassium. Use Caution/Monitor.

            • ammonium chloride

              dichlorphenamide and ammonium chloride both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, ammonium chloride. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • amphotericin B cholesteryl sulfate

              dichlorphenamide and amphotericin B cholesteryl sulfate both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, amphotericin B cholesteryl sulfate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • amphotericin B deoxycholate

              dichlorphenamide and amphotericin B deoxycholate both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, amphotericin B deoxycholate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • amphotericin B liposomal

              dichlorphenamide and amphotericin B liposomal both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, amphotericin B liposomal. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • amphotericin B phospholipid complex

              dichlorphenamide and amphotericin B phospholipid complex both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, amphotericin B phospholipid complex. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • aprepitant

              dichlorphenamide and aprepitant both decrease serum potassium. Use Caution/Monitor.

            • arformoterol

              dichlorphenamide and arformoterol both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, arformoterol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • arginine

              dichlorphenamide, arginine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • aripiprazole

              dichlorphenamide and aripiprazole both decrease serum potassium. Use Caution/Monitor.

            • atenolol

              dichlorphenamide and atenolol both decrease serum potassium. Use Caution/Monitor.

            • azacitidine

              dichlorphenamide and azacitidine both decrease serum potassium. Use Caution/Monitor.

            • azithromycin

              dichlorphenamide and azithromycin both decrease serum potassium. Use Caution/Monitor.

            • basiliximab

              dichlorphenamide and basiliximab both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, basiliximab. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • belatacept

              dichlorphenamide and belatacept both decrease serum potassium. Use Caution/Monitor.

            • belinostat

              dichlorphenamide and belinostat both decrease serum potassium. Use Caution/Monitor.

            • bendamustine

              dichlorphenamide and bendamustine both decrease serum potassium. Use Caution/Monitor.

            • betamethasone

              dichlorphenamide and betamethasone both decrease serum potassium. Use Caution/Monitor.

            • betaxolol

              dichlorphenamide and betaxolol both decrease serum potassium. Use Caution/Monitor.

            • bevacizumab

              dichlorphenamide and bevacizumab both decrease serum potassium. Use Caution/Monitor.

            • bisacodyl

              dichlorphenamide and bisacodyl both decrease serum potassium. Use Caution/Monitor.

            • bisoprolol

              dichlorphenamide and bisoprolol both decrease serum potassium. Use Caution/Monitor.

            • blinatumomab

              dichlorphenamide and blinatumomab both decrease serum potassium. Use Caution/Monitor.

            • bortezomib

              dichlorphenamide and bortezomib both decrease serum potassium. Use Caution/Monitor.

            • budesonide

              dichlorphenamide and budesonide both decrease serum potassium. Use Caution/Monitor.

            • bumetanide

              dichlorphenamide and bumetanide both decrease serum potassium. Use Caution/Monitor.

            • busulfan

              dichlorphenamide and busulfan both decrease serum potassium. Use Caution/Monitor.

            • cabozantinib

              dichlorphenamide and cabozantinib both decrease serum potassium. Use Caution/Monitor.

            • capecitabine

              dichlorphenamide and capecitabine both decrease serum potassium. Use Caution/Monitor.

            • capreomycin

              dichlorphenamide and capreomycin both decrease serum potassium. Use Caution/Monitor.

            • carboplatin

              dichlorphenamide and carboplatin both decrease serum potassium. Use Caution/Monitor.

            • carfilzomib

              dichlorphenamide and carfilzomib both decrease serum potassium. Use Caution/Monitor.

            • carmustine

              dichlorphenamide and carmustine both decrease serum potassium. Use Caution/Monitor.

            • carvedilol

              dichlorphenamide and carvedilol both decrease serum potassium. Use Caution/Monitor.

            • caspofungin

              dichlorphenamide and caspofungin both decrease serum potassium. Use Caution/Monitor.

            • ceftaroline

              dichlorphenamide and ceftaroline both decrease serum potassium. Use Caution/Monitor.

            • celecoxib

              dichlorphenamide and celecoxib both decrease serum potassium. Use Caution/Monitor.

            • cenobamate

              cenobamate, dichlorphenamide. Either increases effects of the other by sedation. Use Caution/Monitor.

            • cetuximab

              dichlorphenamide and cetuximab both decrease serum potassium. Use Caution/Monitor.

            • cevimeline

              dichlorphenamide and cevimeline both decrease serum potassium. Use Caution/Monitor.

            • chlorothiazide

              dichlorphenamide and chlorothiazide both decrease serum potassium. Use Caution/Monitor.

            • chlorthalidone

              dichlorphenamide and chlorthalidone both decrease serum potassium. Use Caution/Monitor.

            • cidofovir

              dichlorphenamide and cidofovir both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, cidofovir. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • ciprofloxacin

              dichlorphenamide and ciprofloxacin both decrease serum potassium. Use Caution/Monitor.

            • cisplatin

              dichlorphenamide and cisplatin both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, cisplatin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • citalopram

              dichlorphenamide and citalopram both decrease serum potassium. Use Caution/Monitor.

            • clomipramine

              dichlorphenamide and clomipramine both decrease serum potassium. Use Caution/Monitor.

            • conivaptan

              dichlorphenamide and conivaptan both decrease serum potassium. Use Caution/Monitor.

            • crizotinib

              dichlorphenamide and crizotinib both decrease serum potassium. Use Caution/Monitor.

            • cyanocobalamin

              dichlorphenamide and cyanocobalamin both decrease serum potassium. Use Caution/Monitor.

            • cytarabine

              dichlorphenamide and cytarabine both decrease serum potassium. Use Caution/Monitor.

            • dabrafenib

              dichlorphenamide and dabrafenib both decrease serum potassium. Use Caution/Monitor.

            • dasatinib

              dichlorphenamide and dasatinib both decrease serum potassium. Use Caution/Monitor.

            • decitabine

              dichlorphenamide and decitabine both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, decitabine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • deferiprone

              dichlorphenamide, deferiprone. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • desflurane

              dichlorphenamide and desflurane both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, desflurane. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • dexamethasone

              dichlorphenamide and dexamethasone both decrease serum potassium. Use Caution/Monitor.

            • dexlansoprazole

              dichlorphenamide and dexlansoprazole both decrease serum potassium. Use Caution/Monitor.

            • dexmedetomidine

              dichlorphenamide and dexmedetomidine both decrease serum potassium. Use Caution/Monitor.

            • dextrose (Antidote)

              dichlorphenamide and dextrose (Antidote) both decrease serum potassium. Use Caution/Monitor.

            • digoxin

              dichlorphenamide and digoxin both decrease serum potassium. Use Caution/Monitor.

            • dinutuximab

              dichlorphenamide and dinutuximab both decrease serum potassium. Use Caution/Monitor.

            • disopyramide

              dichlorphenamide and disopyramide both decrease serum potassium. Use Caution/Monitor.

            • dobutamine

              dichlorphenamide and dobutamine both decrease serum potassium. Use Caution/Monitor.

            • donepezil

              dichlorphenamide and donepezil both decrease serum potassium. Use Caution/Monitor.

            • doxepin

              dichlorphenamide and doxepin both decrease serum potassium. Use Caution/Monitor.

            • doxorubicin

              dichlorphenamide and doxorubicin both decrease serum potassium. Use Caution/Monitor.

            • doxorubicin liposomal

              dichlorphenamide and doxorubicin liposomal both decrease serum potassium. Use Caution/Monitor.

            • dronedarone

              dichlorphenamide and dronedarone both decrease serum potassium. Use Caution/Monitor.

            • duloxetine

              dichlorphenamide and duloxetine both decrease serum potassium. Use Caution/Monitor.

            • edetate calcium disodium

              dichlorphenamide and edetate calcium disodium both decrease serum potassium. Use Caution/Monitor.

            • epinephrine

              dichlorphenamide and epinephrine both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, epinephrine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • epoetin alfa

              dichlorphenamide and epoetin alfa both decrease serum potassium. Use Caution/Monitor.

            • eprosartan

              dichlorphenamide and eprosartan both decrease serum potassium. Use Caution/Monitor.

            • eribulin

              dichlorphenamide and eribulin both decrease serum potassium. Use Caution/Monitor.

            • erlotinib

              dichlorphenamide and erlotinib both decrease serum potassium. Use Caution/Monitor.

            • ertapenem

              dichlorphenamide and ertapenem both decrease serum potassium. Use Caution/Monitor.

            • escitalopram

              dichlorphenamide, escitalopram. sedation. Use Caution/Monitor.

            • esomeprazole

              dichlorphenamide and esomeprazole both decrease serum potassium. Use Caution/Monitor.

            • eszopiclone

              dichlorphenamide and eszopiclone both decrease serum potassium. Use Caution/Monitor.

            • ethacrynic acid

              dichlorphenamide and ethacrynic acid both decrease serum potassium. Use Caution/Monitor.

            • etoposide

              dichlorphenamide, etoposide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • everolimus

              dichlorphenamide and everolimus both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, everolimus. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • febuxostat

              dichlorphenamide and febuxostat both decrease serum potassium. Use Caution/Monitor.

            • felbamate

              dichlorphenamide and felbamate both decrease serum potassium. Use Caution/Monitor.

            • fenoldopam

              dichlorphenamide and fenoldopam both decrease serum potassium. Use Caution/Monitor.

            • fentanyl

              dichlorphenamide and fentanyl both decrease serum potassium. Use Caution/Monitor.

            • fentanyl intranasal

              dichlorphenamide and fentanyl intranasal both decrease serum potassium. Use Caution/Monitor.

            • fentanyl transdermal

              dichlorphenamide and fentanyl transdermal both decrease serum potassium. Use Caution/Monitor.

            • fentanyl transmucosal

              dichlorphenamide and fentanyl transmucosal both decrease serum potassium. Use Caution/Monitor.

            • fidaxomicin

              dichlorphenamide, fidaxomicin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • fluconazole

              dichlorphenamide and fluconazole both decrease serum potassium. Use Caution/Monitor.

            • flucytosine

              dichlorphenamide and flucytosine both decrease serum potassium. Use Caution/Monitor.

            • fludarabine

              dichlorphenamide, fludarabine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • fludrocortisone

              dichlorphenamide and fludrocortisone both decrease serum potassium. Use Caution/Monitor.

            • fluoxetine

              dichlorphenamide and fluoxetine both decrease serum potassium. Use Caution/Monitor.

            • fluvoxamine

              dichlorphenamide and fluvoxamine both decrease serum potassium. Use Caution/Monitor.

            • fondaparinux

              dichlorphenamide and fondaparinux both decrease serum potassium. Use Caution/Monitor.

            • formoterol

              dichlorphenamide and formoterol both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, formoterol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • foscarnet

              dichlorphenamide and foscarnet both decrease serum potassium. Use Caution/Monitor.

            • fosphenytoin

              dichlorphenamide and fosphenytoin both decrease serum potassium. Use Caution/Monitor.

            • furosemide

              dichlorphenamide and furosemide both decrease serum potassium. Use Caution/Monitor.

            • galantamine

              dichlorphenamide and galantamine both decrease serum potassium. Use Caution/Monitor.

            • ganciclovir

              dichlorphenamide and ganciclovir both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, ganciclovir. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • gemcitabine

              dichlorphenamide and gemcitabine both decrease serum potassium. Use Caution/Monitor.

            • gemifloxacin

              dichlorphenamide and gemifloxacin both decrease serum potassium. Use Caution/Monitor.

            • gentamicin

              dichlorphenamide and gentamicin both decrease serum potassium. Use Caution/Monitor.

            • glucagon intranasal

              dichlorphenamide and glucagon intranasal both decrease serum potassium. Use Caution/Monitor.

            • hetastarch

              dichlorphenamide, hetastarch. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • hydrochlorothiazide

              dichlorphenamide and hydrochlorothiazide both decrease serum potassium. Use Caution/Monitor.

            • hydrocodone

              dichlorphenamide and hydrocodone both decrease serum potassium. Use Caution/Monitor.

            • hydrocortisone

              dichlorphenamide and hydrocortisone both decrease serum potassium. Use Caution/Monitor.

            • hydromorphone

              dichlorphenamide and hydromorphone both decrease serum potassium. Use Caution/Monitor.

            • hydroxyurea

              dichlorphenamide, hydroxyurea. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • ibuprofen

              dichlorphenamide, ibuprofen. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • ibuprofen IV

              dichlorphenamide, ibuprofen IV. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • ifosfamide

              dichlorphenamide and ifosfamide both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, ifosfamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • iloperidone

              dichlorphenamide and iloperidone both decrease serum potassium. Use Caution/Monitor.

            • imatinib

              dichlorphenamide and imatinib both decrease serum potassium. Use Caution/Monitor.

            • indacaterol, inhaled

              dichlorphenamide and indacaterol, inhaled both decrease serum potassium. Use Caution/Monitor.

            • indapamide

              dichlorphenamide and indapamide both decrease serum potassium. Use Caution/Monitor.

            • insulin aspart

              dichlorphenamide and insulin aspart both decrease serum potassium. Use Caution/Monitor.

            • insulin degludec

              dichlorphenamide and insulin degludec both decrease serum potassium. Use Caution/Monitor.

            • insulin degludec/insulin aspart

              dichlorphenamide and insulin degludec/insulin aspart both decrease serum potassium. Use Caution/Monitor.

            • insulin detemir

              dichlorphenamide and insulin detemir both decrease serum potassium. Use Caution/Monitor.

            • insulin glargine

              dichlorphenamide and insulin glargine both decrease serum potassium. Use Caution/Monitor.

            • insulin glulisine

              dichlorphenamide and insulin glulisine both decrease serum potassium. Use Caution/Monitor.

            • insulin inhaled

              dichlorphenamide and insulin inhaled both decrease serum potassium. Use Caution/Monitor.

            • insulin lispro

              dichlorphenamide and insulin lispro both decrease serum potassium. Use Caution/Monitor.

            • insulin NPH

              dichlorphenamide and insulin NPH both decrease serum potassium. Use Caution/Monitor.

            • insulin regular human

              dichlorphenamide and insulin regular human both decrease serum potassium. Use Caution/Monitor.

            • interferon gamma 1b

              dichlorphenamide and interferon gamma 1b both decrease serum potassium. Use Caution/Monitor.

            • irinotecan

              dichlorphenamide and irinotecan both decrease serum potassium. Use Caution/Monitor.

            • isoniazid

              dichlorphenamide, isoniazid. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • isosorbide mononitrate

              dichlorphenamide and isosorbide mononitrate both decrease serum potassium. Use Caution/Monitor.

            • ixabepilone

              dichlorphenamide and ixabepilone both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, ixabepilone. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • lactulose

              dichlorphenamide and lactulose both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, lactulose. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • leflunomide

              dichlorphenamide and leflunomide both decrease serum potassium. Use Caution/Monitor.

            • lenalidomide

              dichlorphenamide and lenalidomide both decrease serum potassium. Use Caution/Monitor.

            • lenvatinib

              dichlorphenamide and lenvatinib both decrease serum potassium. Use Caution/Monitor.

            • leuprolide

              dichlorphenamide and leuprolide both decrease serum potassium. Use Caution/Monitor.

            • levalbuterol

              dichlorphenamide and levalbuterol both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, levalbuterol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • lorazepam

              dichlorphenamide, lorazepam. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • mafenide

              dichlorphenamide, mafenide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • magnesium sulfate

              dichlorphenamide and magnesium sulfate both decrease serum potassium. Use Caution/Monitor.

            • mannitol

              dichlorphenamide and mannitol both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, mannitol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • meropenem

              dichlorphenamide and meropenem both decrease serum potassium. Use Caution/Monitor.

            • metaproterenol

              dichlorphenamide and metaproterenol both decrease serum potassium. Use Caution/Monitor.

            • metformin

              dichlorphenamide, metformin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • methadone

              dichlorphenamide and methadone both decrease serum potassium. Use Caution/Monitor.

            • methazolamide

              dichlorphenamide and methazolamide both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, methazolamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • methyclothiazide

              dichlorphenamide and methyclothiazide both decrease serum potassium. Use Caution/Monitor.

            • methylprednisolone

              dichlorphenamide and methylprednisolone both decrease serum potassium. Use Caution/Monitor.

            • metolazone

              dichlorphenamide and metolazone both decrease serum potassium. Use Caution/Monitor.

            • micafungin

              dichlorphenamide and micafungin both decrease serum potassium. Use Caution/Monitor.

            • midazolam intranasal

              midazolam intranasal, dichlorphenamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.

            • mifepristone

              dichlorphenamide and mifepristone both decrease serum potassium. Use Caution/Monitor.

            • milrinone

              dichlorphenamide and milrinone both decrease serum potassium. Use Caution/Monitor.

            • minocycline

              dichlorphenamide, minocycline. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • mitoxantrone

              dichlorphenamide and mitoxantrone both decrease serum potassium. Use Caution/Monitor.

            • morphine

              dichlorphenamide and morphine both decrease serum potassium. Use Caution/Monitor.

            • moxifloxacin

              dichlorphenamide and moxifloxacin both decrease serum potassium. Use Caution/Monitor.

            • mycophenolate

              dichlorphenamide and mycophenolate both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, mycophenolate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • nabumetone

              dichlorphenamide and nabumetone both decrease serum potassium. Use Caution/Monitor.

            • naproxen

              dichlorphenamide and naproxen both decrease serum potassium. Use Caution/Monitor.

            • nelarabine

              dichlorphenamide and nelarabine both decrease serum potassium. Use Caution/Monitor.

            • nelfinavir

              dichlorphenamide, nelfinavir. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • nilotinib

              dichlorphenamide and nilotinib both decrease serum potassium. Use Caution/Monitor.

            • nisoldipine

              dichlorphenamide and nisoldipine both decrease serum potassium. Use Caution/Monitor.

            • nitric oxide gas

              dichlorphenamide and nitric oxide gas both decrease serum potassium. Use Caution/Monitor.

            • nitroprusside sodium

              dichlorphenamide, nitroprusside sodium. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • nivolumab

              dichlorphenamide and nivolumab both decrease serum potassium. Use Caution/Monitor.

            • obinutuzumab

              dichlorphenamide and obinutuzumab both decrease serum potassium. Use Caution/Monitor.

            • olodaterol inhaled

              dichlorphenamide and olodaterol inhaled both decrease serum potassium. Use Caution/Monitor.

            • omeprazole

              dichlorphenamide and omeprazole both decrease serum potassium. Use Caution/Monitor.

            • ondansetron

              dichlorphenamide and ondansetron both decrease serum potassium. Use Caution/Monitor.

            • oprelvekin

              dichlorphenamide and oprelvekin both decrease serum potassium. Use Caution/Monitor.

            • oxcarbazepine

              dichlorphenamide and oxcarbazepine both decrease serum potassium. Use Caution/Monitor.

            • oxycodone

              dichlorphenamide, oxycodone. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • paclitaxel

              dichlorphenamide and paclitaxel both decrease serum potassium. Use Caution/Monitor.

            • paclitaxel protein bound

              dichlorphenamide and paclitaxel protein bound both decrease serum potassium. Use Caution/Monitor.

            • palonosetron

              dichlorphenamide and palonosetron both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, palonosetron. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • pamidronate

              dichlorphenamide and pamidronate both decrease serum potassium. Use Caution/Monitor.

            • panitumumab

              dichlorphenamide and panitumumab both decrease serum potassium. Use Caution/Monitor.

            • panobinostat

              dichlorphenamide and panobinostat both decrease serum potassium. Use Caution/Monitor.

            • paroxetine

              dichlorphenamide and paroxetine both decrease serum potassium. Use Caution/Monitor.

            • pasireotide

              dichlorphenamide and pasireotide both decrease serum potassium. Use Caution/Monitor.

            • phenelzine

              dichlorphenamide, phenelzine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • phentermine

              dichlorphenamide and phentermine both decrease serum potassium. Use Caution/Monitor.

            • piperacillin

              dichlorphenamide and piperacillin both decrease serum potassium. Use Caution/Monitor.

            • polyethylene glycol & electrolytes

              dichlorphenamide and polyethylene glycol & electrolytes both decrease serum potassium. Use Caution/Monitor.

            • pomalidomide

              dichlorphenamide and pomalidomide both decrease serum potassium. Use Caution/Monitor.

            • ponatinib

              dichlorphenamide and ponatinib both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, ponatinib. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • posaconazole

              dichlorphenamide and posaconazole both decrease serum potassium. Use Caution/Monitor.

            • potassium phosphates, IV

              dichlorphenamide and potassium phosphates, IV both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, potassium phosphates, IV. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • pralatrexate

              dichlorphenamide and pralatrexate both decrease serum potassium. Use Caution/Monitor.

            • prednisone

              dichlorphenamide and prednisone both decrease serum potassium. Use Caution/Monitor.

            • propafenone

              dichlorphenamide and propafenone both decrease serum potassium. Use Caution/Monitor.

            • propofol

              dichlorphenamide, propofol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • prothrombin complex concentrate, human

              dichlorphenamide and prothrombin complex concentrate, human both decrease serum potassium. Use Caution/Monitor.

            • pyridoxine

              dichlorphenamide, pyridoxine. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • quetiapine

              dichlorphenamide and quetiapine both decrease serum potassium. Use Caution/Monitor.

            • regorafenib

              dichlorphenamide and regorafenib both decrease serum potassium. Use Caution/Monitor.

            • riluzole

              dichlorphenamide and riluzole both decrease serum potassium. Use Caution/Monitor.

            • rivastigmine

              dichlorphenamide and rivastigmine both decrease serum potassium. Use Caution/Monitor.

            • romidepsin

              dichlorphenamide and romidepsin both decrease serum potassium. Use Caution/Monitor.

            • ropinirole

              dichlorphenamide and ropinirole both decrease serum potassium. Use Caution/Monitor.

            • salmeterol

              dichlorphenamide and salmeterol both decrease serum potassium. Use Caution/Monitor.

            • selegiline

              dichlorphenamide and selegiline both decrease serum potassium. Use Caution/Monitor.

            • senna

              dichlorphenamide and senna both decrease serum potassium. Use Caution/Monitor.

            • sevelamer

              dichlorphenamide, sevelamer. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • sirolimus

              dichlorphenamide and sirolimus both decrease serum potassium. Use Caution/Monitor.

            • sodium phosphates, IV

              dichlorphenamide and sodium phosphates, IV both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, sodium phosphates, IV. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • sorafenib

              dichlorphenamide and sorafenib both decrease serum potassium. Use Caution/Monitor.

            • sorbitol

              dichlorphenamide, sorbitol. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • spironolactone

              dichlorphenamide, spironolactone. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • stiripentol

              stiripentol, dichlorphenamide. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.

            • sunitinib

              dichlorphenamide and sunitinib both decrease serum potassium. Use Caution/Monitor.

            • tacrolimus

              dichlorphenamide and tacrolimus both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, tacrolimus. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • temsirolimus

              dichlorphenamide and temsirolimus both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, temsirolimus. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • teniposide

              dichlorphenamide, teniposide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • tenofovir DF

              dichlorphenamide and tenofovir DF both decrease serum potassium. Use Caution/Monitor.

            • terbutaline

              dichlorphenamide and terbutaline both decrease serum potassium. Use Caution/Monitor.

            • thalidomide

              dichlorphenamide and thalidomide both decrease serum potassium. Use Caution/Monitor.

            • theophylline

              dichlorphenamide and theophylline both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, theophylline. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • tiagabine

              dichlorphenamide and tiagabine both decrease serum potassium. Use Caution/Monitor.

            • tigecycline

              dichlorphenamide, tigecycline. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • tobramycin

              dichlorphenamide and tobramycin both decrease serum potassium. Use Caution/Monitor.

            • topiramate

              dichlorphenamide and topiramate both decrease serum potassium. Use Caution/Monitor.

              dichlorphenamide, topiramate. Either increases levels of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • torsemide

              dichlorphenamide and torsemide both decrease serum potassium. Use Caution/Monitor.

            • trametinib

              dichlorphenamide and trametinib both decrease serum potassium. Use Caution/Monitor.

            • trastuzumab deruxtecan

              dichlorphenamide and trastuzumab deruxtecan both decrease serum potassium. Use Caution/Monitor.

            • treprostinil

              dichlorphenamide and treprostinil both decrease serum potassium. Use Caution/Monitor.

            • tretinoin

              dichlorphenamide, tretinoin. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • triamcinolone acetonide injectable suspension

              dichlorphenamide and triamcinolone acetonide injectable suspension both decrease serum potassium. Use Caution/Monitor.

            • triamterene

              dichlorphenamide, triamterene. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • valganciclovir

              dichlorphenamide and valganciclovir both decrease serum potassium. Use Caution/Monitor.

            • vancomycin

              dichlorphenamide and vancomycin both decrease serum potassium. Use Caution/Monitor.

            • vandetanib

              dichlorphenamide and vandetanib both decrease serum potassium. Use Caution/Monitor.

            • varenicline

              dichlorphenamide and varenicline both decrease serum potassium. Use Caution/Monitor.

            • venlafaxine

              dichlorphenamide and venlafaxine both decrease serum potassium. Use Caution/Monitor.

            • vismodegib

              dichlorphenamide and vismodegib both decrease serum potassium. Use Caution/Monitor.

            • vitamin A

              dichlorphenamide, vitamin A. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            • voriconazole

              dichlorphenamide and voriconazole both decrease serum potassium. Use Caution/Monitor.

            • vorinostat

              dichlorphenamide and vorinostat both decrease serum potassium. Use Caution/Monitor.

            • ziprasidone

              dichlorphenamide and ziprasidone both decrease serum potassium. Use Caution/Monitor.

            • zoledronic acid

              dichlorphenamide and zoledronic acid both decrease serum potassium. Use Caution/Monitor.

            • zonisamide

              dichlorphenamide, zonisamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Both drugs can cause metabolic acidosis.

            Minor (0)

              Previous
              Next:

              Adverse Effects

              >10%

              Paresthesia (44%)

              Cognitive disorder (14%)

              Dysgeusia (14%)

              Confusional state (11%)

              1-10%

              Headache (8%)

              Hypoesthesia (8%)

              Lethargy (8%)

              Fatigue (8%)

              Muscle spasms (8%)

              Rash (8%)

              Dizziness (6%)

              Diarrhea (6%)

              Nausea (6%)

              Malaise (6%)

              Decreased weight (6%)

              Arthralgia (6%)

              Muscle twitching (6%)

              Dyspnea (6%)

              Pharyngolaryngeal pain (6%)

              Pruritus (6%)

              Postmarketing Reports

              Amnesia

              Cardiac failure

              Convulsion

              Fetal death

              Hallucination

              Nephrolithiasis

              Pancytopenia

              Psychotic disorder

              Renal tubular necrosis

              Stupor

              Syncope

              Tremor

              Previous
              Next:

              Warnings

              Contraindications

              Hypersensitivity to dichlorphenamide or other sulfonamides

              Coadministration with high-dose aspirin

              Severe pulmonary disease, limiting compensation to metabolic acidosis caused by dichlorphenamide

              Hepatic insufficiency; dichlorphenamide may aggravate hepatic encephalopathy

              Cautions

              Fatalities associated with sulfonamides reported; hypersensitivity, anaphylaxis, and idiosyncratic reactions reported and may include Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias; pulmonary symptoms may occur in isolation or as part of a systemic reaction; discontinue at first sign of rash

              Dichlorphenamide increases potassium excretion and may cause hypokalemiareported; monitor potassium levels periodically; risk is greater when used with conditions associated with hypokalemia (eg, adrenocortical insufficiency, hyperchloremic metabolic acidosis, respiratory acidosis) and in patients receiving other drugs that may cause hypokalemia; if hypokalemia develops or persists, consider dose reduction or discontinuation of drug, and correct serum potassium

              Can cause hyperchloremic nonanion gap metabolic acidosis; coadministration with other drugs that cause metabolic acidosis may increase the severity; measure bicarbonate at baseline and then periodically; if metabolic acidosis develops or persists, consider reducing dose or discontinuing the drug

              Increased risk of falls; risk is greater in elderly patients and with higher doses

              Drug interaction overview

              • Aspirin and other salicylates
                • Carbonic anhydrase inhibitors, including dichlorphenamide, can cause metabolic acidosis, which may increase salicylate toxicity
                • Contraindicated with high-dose aspirin owing to risk of anorexia, tachypnea, lethargy, and coma
                • Monitor carefully if coadministered with low-dose aspirin
              • OAT1 substrates
                • Dichlorphenamide is an inhibitor of OAT1 transporters in vitro
                • Coadministration may increase plasma exposure of OAT1 substrates
                • Use with sensitive OAT1 substrates (methotrexate, famotidine, oseltamivir) is not recommended
              • OAT1/3 inhibitors
                • Dichlorphenamide is a substrate of human transporters OAT1 and OAT3
                • Monitor for signs of dichlorphenamide toxicity if coadministered with OAT1 or OAT3 inhibitors
              • Drug-induced hypokalemia
                • Hypokalemia risk increases if coadministered with other drugs that decrease serum potassium (eg, loop diuretics, thiazide diuretics, laxatives, antifungals, penicillin, theophylline)
              • Drug-induced metabolic acidosis
                • Coadministration with other drugs that cause metabolic acidosis may increase acidosis severity
              Previous
              Next:

              Pregnancy & Lactation

              Pregnancy

              Data are not available on the developmental risk associated with the use in pregnant women

              Animal studies

              • Dichlorphenamide was teratogenic when administered orally to pregnant rats; fetal limb reduction defects observed at 17 x MRHD

              Clinical considerations

              • Treatment can cause metabolic acidosis
              • Effect of dichlorphenamide-induced metabolic acidosis has not been studied in pregnancy; however, metabolic acidosis in pregnancy (due to other causes) can cause decreased fetal growth, decreased fetal oxygenation, and fetal death, and may affect the fetus’ ability to tolerate labor
              • Monitor pregnant women for metabolic acidosis and treat as in the nonpregnant state
              • Monitor newborns of mothers treated with dichlorphenamide for metabolic acidosis because of possible occurrence of transient metabolic acidosis following birth
              • Labor or delivery
                • Although the effect on labor and delivery in humans has not been established, the development of dichlorphenamide-induced metabolic acidosis in the mother and/or in the fetus might affect the fetus’ ability to tolerate labor

              Lactation

              Unknown if distributed in human breast milk

              Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

              Pregnancy Categories

              A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

              B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

              C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

              D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

              X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

              NA: Information not available.

              Previous
              Next:

              Pharmacology

              Mechanism of Action

              Carbonic anhydrase inhibitor, but the exact mechanism by which dichlorphenamide is able to treat periodic paralysis is unknown

              Dichlorphenamide helps to normalize blood-potassium levels by decreasing levels

              Absorption

              Peak plasma time: 1.5-3 hr

              Steady-state achieved: Within 10 days of twice-daily dosing

              Distribution

              Protein bound: 88%

              Metabolism

              Not a substrate of CYP isoenzymes

              Elimination

              Half-life: 32-66 hr

              Previous
              Next:

              Administration

              Oral Administration

              May take with or without food

              Storage

              Store at controlled room temperature of 20-25ºC (68-77ºF)

              Previous
              Next:

              Images

              No images available for this drug.
              Previous
              Next:

              Patient Handout

              Patient Education
              dichlorphenamide oral

              DICHLORPHENAMIDE - ORAL

              (DYE-klor-FEN-a-mide)

              COMMON BRAND NAME(S): Keveyis

              USES: This medication is used to treat a certain inherited condition that causes attacks of muscle weakness or loss of muscle movement that come and go (primary periodic paralysis). Dichlorphenamide belongs to a class of drugs known as carbonic anhydrase inhibitors. It is not known how it works for this condition, but it can decrease the number of attacks of muscle weakness.

              HOW TO USE: Take this medication by mouth as directed by your doctor, usually once or twice daily. The dosage is based on your medical condition and response to treatment.Use this medication regularly to get the most benefit from it. To help you remember, take it at the same time(s) each day.Tell your doctor if your condition does not get better or if it gets worse.

              SIDE EFFECTS: Numbness/tingling, change in the sense of taste, nausea, diarrhea, weight loss, muscle spasms/twitching, tiredness, dizziness, or drowsiness may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.Dizziness can increase the risk of falling. Get up slowly when rising from a sitting or lying position.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: easy bleeding/bruising, rapid breathing, unusual tiredness, mental/mood changes (such as confusion, inability to think clearly), signs of low potassium level in the blood (such as muscle cramps, irregular heartbeat).A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

              PRECAUTIONS: Before taking dichlorphenamide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: adrenal gland problems (such as Addison's disease), liver problems, breathing problems (such as asthma, chronic obstructive lung disease-COPD).This drug may make you dizzy or drowsy. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Tell your doctor right away if you get sunburned or have skin blisters/redness.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Older adults may be at greater risk for falls or low bicarbonate levels while using this drug.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.It is unknown if this medication passes into breast milk. Consult your doctor before breast-feeding.

              DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug are: aspirin (in high doses used to treat pain), salicylates, methenamine.If your doctor has directed you to take low-dose aspirin for heart attack or stroke prevention (usually 81-162 milligrams a day), you should continue taking the aspirin unless your doctor instructs you otherwise.

              OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: shaking (tremors), ringing in the ears.

              NOTES: Do not share this medication with others.Lab and/or medical tests (such as bicarbonate and potassium blood levels) should be done before you start taking this medication and while you are taking it. Keep all medical and lab appointments.

              MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

              STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

              Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.

              IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

              Previous
              Next:

              Formulary

              FormularyPatient Discounts

              Adding plans allows you to compare formulary status to other drugs in the same class.

              To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

              Adding plans allows you to:

              • View the formulary and any restrictions for each plan.
              • Manage and view all your plans together – even plans in different states.
              • Compare formulary status to other drugs in the same class.
              • Access your plan list on any device – mobile or desktop.

              The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

              Tier Description
              1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
              2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
              3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
              4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
              NC NOT COVERED – Drugs that are not covered by the plan.
              Code Definition
              PA Prior Authorization
              Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
              QL Quantity Limits
              Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
              ST Step Therapy
              Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
              OR Other Restrictions
              Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
              Additional Offers
              Email to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Email Forms to Patient

              From:

              To:

              The recipient will receive more details and instructions to access this offer.

              By clicking send, you acknowledge that you have permission to email the recipient with this information.

              Previous
              Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.